Extract
A lung transplant recipient has suddenly developed new circulating donor-specific antibodies (DSAs). Are these antibodies causing antibody-mediated allograft injury or are they merely a marker of immune activation? Should one treat the patients with no allograft dysfunction? Are some DSAs more important than others? Yet another patient appears to have chronic lung allograft dysfunction (CLAD) and yet no history of circulating DSAs. In these increasingly recognised scenarios, how should the transplant physician respond?
Abstract
Intragraft DSA can be found in explanted lungs of patients with chronic lung allograft dysfunction in the absence of circulating DSA. New diagnostic approaches to assess for intragraft DSA may add to our diagnostic arsenal in treating AMR. http://bit.ly/31kS00b
Footnotes
Conflict of interest: J.M. Tikkanen has nothing to disclose.
Conflict of interest: K. Tinckam has nothing to disclose.
- Received October 1, 2019.
- Accepted October 11, 2019.
- Copyright ©ERS 2019